# GCNT7

## Overview
GCNT7, or glucosaminyl (N-acetyl) transferase family member 7, is a gene that encodes a glycosyltransferase enzyme involved in the glycosylation process, a critical post-translational modification of proteins and lipids. This enzyme is responsible for the transfer of N-acetylglucosamine to specific substrates, a key step in the synthesis of complex carbohydrates. The protein encoded by GCNT7 operates primarily within the Golgi apparatus, where it plays a significant role in modifying proteins and lipids, thereby influencing cellular communication and immune responses (Hansen2014A; Narimatsu2018A). As a glycosyltransferase, GCNT7 is implicated in various cellular functions and disease processes, including neurodegenerative diseases like Alzheimer's and pathogen-driven infections, highlighting its potential as a therapeutic target (Hossain2022Pathogendriven; FrenkelPinter2017Altered).

## Function
GCNT7 (glucosaminyl (N-acetyl) transferase family member 7) is an enzyme involved in the glycosylation process, which is essential for the proper folding, stability, and function of proteins. This enzyme specifically catalyzes the transfer of N-acetylglucosamine to substrates, a critical step in the synthesis of complex carbohydrates. GCNT7 operates within the Golgi apparatus, where it contributes to the modification of proteins and lipids, impacting cellular communication and immune responses (Hansen2014A).

In the context of healthy human cells, GCNT7 plays a role in the glycosylation pathways that are crucial for various cellular functions. These pathways are involved in the biosynthesis of glycans, which are important for cell signaling and interactions. The enzyme's activity in the Golgi apparatus ensures that proteins are correctly modified, which is vital for their function and for maintaining cellular homeostasis (Narimatsu2018A).

While specific details about GCNT7's function in healthy cells are limited, its involvement in glycosylation suggests it has a significant role in maintaining normal cellular processes and organismal health (Hansen2014A).

## Clinical Significance
GCNT7 has been implicated in several diseases due to its role in glycosylation. Altered expression of GCNT7 is significant in predicting Alzheimer's disease (AD) pathology, particularly in the hippocampus and entorhinal cortex. The gene is upregulated in AD, and its involvement in various glycosylation pathways suggests that changes in its expression may be clinically significant in the context of AD (FrenkelPinter2017Altered).

In the context of pathogen-driven diseases, GCNT7 is identified as an upregulated hub protein in response to infections by pathogens such as E. coli and Salmonella. It interacts with other proteins like ADAMTS1 and JAZF1, which are also upregulated due to Salmonella pathogenesis. These interactions suggest that GCNT7 may play a role in diseases associated with these pathogens, potentially serving as a therapeutic target (Hossain2022Pathogendriven).

While GCNT7's role in congenital disorders of glycosylation (CDGs) is not specifically mentioned, the broader context of glycosyltransferases in glycosylation-related diseases suggests that mutations or alterations in GCNT7 could contribute to disease phenotypes, although specific mutations in GCNT7 have not been detailed in the provided context (Hansen2014A).

## Interactions
GCNT7, a protein involved in glycosylation, participates in several notable interactions with other proteins. It has been identified as a hub protein with stable interactions with proteins such as HIST1H2BC and RPS6, which are upregulated in response to infections by Shigella and Campylobacter, respectively. These interactions suggest a role for GCNT7 in the pathogenesis of infections caused by multiple bacterial species (Hossain2022Pathogendriven). 

GCNT7 also interacts with ADAMTS1 and JAZF1, which are upregulated hub proteins associated with Salmonella pathogenesis. The stability of these interactions was confirmed through molecular dynamics simulations, which assessed parameters such as root mean square deviation (RMSD), hydrogen bonding, and solvent-accessible surface area (SASA) (Hossain2022Pathogendriven). 

In the context of Alzheimer's disease, GCNT7 is upregulated and involved in UDP-glycosyltransferase activity, indicating its participation in glycosylation pathways that may influence disease pathology. This suggests that GCNT7's interactions extend beyond infectious diseases to include roles in neurodegenerative conditions (FrenkelPinter2017Altered). These interactions highlight GCNT7's potential as a therapeutic target for various diseases.


## References


[1. (FrenkelPinter2017Altered) Moran Frenkel-Pinter, Shiri Stempler, Sharon Tal-Mazaki, Yelena Losev, Avnika Singh-Anand, Daniela Escobar-Álvarez, Jonathan Lezmy, Ehud Gazit, Eytan Ruppin, and Daniel Segal. Altered protein glycosylation predicts alzheimer’s disease and modulates its pathology in disease model drosophila. Neurobiology of Aging, 56:159–171, August 2017. URL: http://dx.doi.org/10.1016/j.neurobiolaging.2017.04.020, doi:10.1016/j.neurobiolaging.2017.04.020. This article has 20 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.neurobiolaging.2017.04.020)

[2. (Hansen2014A) Lars Hansen, Allan Lind-Thomsen, Hiren J Joshi, Nis Borbye Pedersen, Christian Theil Have, Yun Kong, Shengjun Wang, Thomas Sparso, Niels Grarup, Malene Bech Vester-Christensen, Katrine Schjoldager, Hudson H Freeze, Torben Hansen, Oluf Pedersen, Bernard Henrissat, Ulla Mandel, Henrik Clausen, Hans H Wandall, and Eric P Bennett. A glycogene mutation map for discovery of diseases of glycosylation. Glycobiology, 25(2):211–224, September 2014. URL: http://dx.doi.org/10.1093/glycob/cwu104, doi:10.1093/glycob/cwu104. This article has 49 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/glycob/cwu104)

[3. (Narimatsu2018A) Yoshiki Narimatsu, Hiren J Joshi, Zhang Yang, Catarina Gomes, Yen-Hsi Chen, Flaminia C Lorenzetti, Sanae Furukawa, Katrine T Schjoldager, Lars Hansen, Henrik Clausen, Eric P Bennett, and Hans H Wandall. A validated grna library for crispr/cas9 targeting of the human glycosyltransferase genome. Glycobiology, 28(5):295–305, January 2018. URL: http://dx.doi.org/10.1093/glycob/cwx101, doi:10.1093/glycob/cwx101. This article has 73 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/glycob/cwx101)

[4. (Hossain2022Pathogendriven) Mohammad Uzzal Hossain, Nadim Ferdous, Mahjerin Nasrin Reza, Ishtiaque Ahammad, Zachary Tiernan, Yi Wang, Fergus O’Hanlon, Zijia Wu, Shishir Sarker, A. K. M. Mohiuddin, Keshob Chandra Das, Chaman Ara Keya, and Md. Salimullah. Pathogen-driven gene expression patterns lead to a novel approach to the identification of common therapeutic targets. Scientific Reports, December 2022. URL: http://dx.doi.org/10.1038/s41598-022-25102-8, doi:10.1038/s41598-022-25102-8. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-022-25102-8)